October 22, 2019 — Drinking small amounts of alcohol frequently is linked with a higher likelihood of atrial ...

October 22, 2019 — OmniVision Technologies Inc. announced that its OV6948 camera module is the winner of the Guinness ...

Elevated left ventricular mass, known as left-ventricular hypertrophy, is a stronger predictor of coronary artery disease-related death and heart failure than coronary artery calcium score, according to a new study published in the journal Radiology.

An algorithm developed by faculty at The University of Texas Health Science Center at Houston (UTHealth) can help physicians outside of major stroke treatment centers assess whether a patient suffering from ischemic stroke would benefit from an endovascular procedure to remove a clot blocking an artery.

A new study published in Clinical Cardiology introduces the North Indian (NORIN) ST‐Segment Elevation Myocardial Infarction (STEMI) Registry and provides preliminary data collected since its start in January of this year. The prospective cohort study’s first author, Sameer Arora, M.D., UNC School of Medicine cardiology fellow and preventive medicine resident, says researchers will follow approximately 3,500 patients admitted for STEMI treatment to two government-funded medical centers in New Delhi, India.

The Bristol-Myers Squibb-Pfizer Alliance and Fitbit announced at the TIME 100 Health Summit in New York that they are working together to help drive timely diagnosis of atrial fibrillation (AFib). The partnership has the aim of improving earlier detection in individuals at increased risk of stroke. The BMS-Pfizer Alliance and Fitbit plan to collaborate on the development of educational content and guidance to support people at increased risk for AFib. Upon submission and U.S. Food and Drug Administration (FDA) clearance of the AFib detection software on Fitbit devices, the parties will aim to provide users with appropriate information to help encourage and inform discussions with their physicians.